Current treatments used in Multiple Sclerosis (MS) are partly effective in the early stages of the disease but display very limited benefits in patients affected by progressive MS. One possible explanation is that these therapies are unable to target the inflammatory component most active during the progressive phase of the disease, and compartmentalized behind the blood-brain barrier. Our findings show that Rapamycin ameliorates clinical and histological signs of chronic EAE when administered during ongoing disease. Moreover, Rapamycin significantly reduced the hyperalgesia observed before clinical development of EAE which, in turn, is completely abolished by the administration of the drug.

Lisi, L., Navarra, P., Cirocchi, R., Sharp, A., Stigliano, E., Feinstein, D. L., Dello Russo, C., Rapamycin reduces clinical signs and neuropathic pain in a chronic model ofexperimental autoimmune encephalomyelitis., <<JOURNAL OF NEUROIMMUNOLOGY>>, 2012; (243): 43-51. [doi:10.1016/j.jneuroim.2011.12.018] [http://hdl.handle.net/10807/6866]

Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis.

Lisi, Lucia;Navarra, Pierluigi;Cirocchi, Roberto;Stigliano, Egidio;Dello Russo, Cinzia
2012

Abstract

Current treatments used in Multiple Sclerosis (MS) are partly effective in the early stages of the disease but display very limited benefits in patients affected by progressive MS. One possible explanation is that these therapies are unable to target the inflammatory component most active during the progressive phase of the disease, and compartmentalized behind the blood-brain barrier. Our findings show that Rapamycin ameliorates clinical and histological signs of chronic EAE when administered during ongoing disease. Moreover, Rapamycin significantly reduced the hyperalgesia observed before clinical development of EAE which, in turn, is completely abolished by the administration of the drug.
Inglese
Lisi, L., Navarra, P., Cirocchi, R., Sharp, A., Stigliano, E., Feinstein, D. L., Dello Russo, C., Rapamycin reduces clinical signs and neuropathic pain in a chronic model ofexperimental autoimmune encephalomyelitis., <<JOURNAL OF NEUROIMMUNOLOGY>>, 2012; (243): 43-51. [doi:10.1016/j.jneuroim.2011.12.018] [http://hdl.handle.net/10807/6866]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/6866
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 47
  • ???jsp.display-item.citation.isi??? ND
social impact